Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488421 | 0.81 | MBNL1 (0.41) | MAPTSMN1; SMN2KDM4EGALR3HTT | |
| SCHEMBL1075576 | 0.79 | MAPT (0.34) | MAPTSMN1; SMN2L3MBTL1LMNAPDE2A | |
| SCHEMBL17023419 | 0.79 | NPC1 (0.47) | MAPTSMN1; SMN2KDM4EHTTL3MBTL1 | |
| SCHEMBL15952575 | 0.77 | MAPT (0.39) | MAPTSMN1; SMN2KDM4EGALR3HTT | |
| SCHEMBL3488733 | 0.76 | KDM4C (0.38) | MAPTSMN1; SMN2KDM4EL3MBTL1LMNA | |
| SCHEMBL3489083 | 0.74 | SLC34A1 (0.45) | MAPTSMN1; SMN2KDM4EGALR3HTT | |
| SCHEMBL3488391 | 0.73 | GRM5 (0.42) | MAPTSMN1; SMN2KDM4EGALR3HTT | |
| SCHEMBL1074098 | 0.73 | PGR (0.41) | MAPTKDM4ECDK8ACVR1BRD4 | |
| SCHEMBL4158211 | 0.73 | MAPT (0.49) | MAPTSMN1; SMN2KDM4EGALR3HTT | |
| SCHEMBL15639816 | 0.73 | BRD4 (0.45) | MAPTSMN1; SMN2LMNANMT1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9131693-B2 | Fungicidal pyrazoles | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2611297-B1 | FUNGICIDAL PYRAZOLES | DU PONT (US) | 2015-06-17 | — | — | EP | disclosed |
| US-20140221448-A1 | FUNGICIDAL PYRAZOLES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-8754115-B2 | Fungicidal pyrazoles | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2611297-A1 | FUNGICIDAL PYRAZOLES | E.I. Du Pont De Nemours And Company (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130143940-A1 | FUNGICIDAL PYRAZOLES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012030922-A1 | FUNGICIDAL PYRAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221448-A1 | FUNGICIDAL PYRAZOLES | CYP1A1, CYP1B1, CYP4X1 | MAPT 3611/4885SMN1; SMN2 3224/4885KDM4E 1961/4885 |
| US-20130143940-A1 | FUNGICIDAL PYRAZOLES | CYP1A1, CYP1B1, CYP4X1 | MAPT 3611/4885SMN1; SMN2 3224/4885KDM4E 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.